FDA Approves Merck ’s Keytruda (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery

Keytruda Is Now Approved for the Adjuvant Treatment of Patients With RCC at Intermediate-High or High Risk of Recurrence Following Nephrectomy, or Following Nephrectomy and Resection of Metastatic Lesions Keytruda Is the First Immunotherapy...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news